BMC Cancer· 2026Q2
Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma – the BELI(E)VE trial
- 0citations
- Q2SCImago
- 2026year
Short summary
The BELI(E)VE trial is evaluating a combination therapy of belantamab mafodotin and venetoclax for relapsed or refractory multiple myeloma patients with a t(11;14) translocation, a specific genetic subtype.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Hematology
HematologyMedicine